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Platinum-based combination chemotherapy has been proven to be superior to single-agent platinum in the treatment of relapsed
ovarian cancer after a treatment-free interval of more than 6 months. A response rate of 41% was previously reported by our group
using a combination of epirubicin, cisplatin and 5-FU in patients who relapsed within 12 months, we therefore assessed a similar, but
more convenient combination of epirubicin, carboplatin and capecitabine in this phase-I/II trial. In total, 18 patients with recurrent
epithelial ovarian carcinoma, who had not received more than two lines of chemotherapy and the treatment-free interval exceeded 6
months were treated with carboplatin AUC5, epirubicin 50mgm
 2 and capecitabine at several dose levels on continuous 21 day
cycles and 14 of 21 day cycles. Patients were assessed for toxicity and by CT and CA-125 for response. The overall response rate was
61.1%, with three complete and eight partial responses. Grade 3/4 haematological toxicity was seen in 10 out of 18 patients and
caused dose reductions and treatment delays. The combination of epirubicin, carboplatin and capecitabine showed good activity but
caused excessive toxicity. A phase-II trial using carboplatin and capecitabine is underway.
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Ovarian cancer remains the number one cause of death from
gynaecological neoplasms in the Western world (Greenlee et al,
2001). Response rates to first-line chemotherapy in women with
ovarian cancer are high but most patients relapse and need further
treatment. Recurrent disease is incurable (Ozols, 2002); however,
many patients can obtain good palliation from further treatment,
particularly if they obtain an objective response (Cannistra, 2002).
Platinum-based combination chemotherapy has been proven to
be superior to single-agent carboplatin in patients with so-called
chemo-sensitive relapsed ovarian cancer in terms of response rate
and progression-free survival in two randomised studies and
overall survival in one of them (Parmar et al, 2003; Pfisterer et al,
2005). Chemo-sensitive relapse is usually defined as one that
occurs after a platinum-free interval of over 6 months.
However, there is uncertainty concerning which agent to add to
carboplatin in this situation: data on the activity of single-agent
non-platinum therapy have shown similar efficacy for paclitaxel
(Piccart et al, 2000), docetaxel (Kaye et al, 1997), epirubicin
(Havsteen et al, 1996), gemcitabine (Shapiro et al, 1996), liposomal
doxorubicin (Muggia et al, 1997; Gordon et al, 2001), etoposide
(Rose et al, 1998), topotecan (Gore et al, 2002), oxaliplatin (Chollet
et al, 1996), and vinorelbine (Sorensen et al, 2001). There is one
analysis that shows superiority for caelyx over topotecan in
patients with a progression-free interval 46 months but this was a
subset analysis (Gordon et al, 2004).
Our group has shown that patients re-challenged with platinum
using a combination of epirubicin, cisplatin and continuous
infusional 5-fluoruracil (ECF) for recurrent ovarian cancer have a
response rate of 41%. In this study, the patients had relapsed
within 12 months of platinum treatment (Ahmed et al, 1995).
Considerable morbidity can be associated with an indwelling
central venous catheter for the administration of 5-FU, such as
pneumothorax at the time of insertion, sepsis or thrombosis. We
therefore decided to investigate the substitution of continuous
intravenous 5-FU in the ECF regimen with capecitabine (Xeloda),
an orally bio-available fluoropyrimidine carbamate. The conver-
sion of the prodrug capecitabine to 5-fluoruracil is dependent on
thymidine phosphorylase, an enzyme preferentially expressed in
malignant cells, and is considered tumour-selective (Ishikawa et al,
1998; Schilsky, 2000). Capecitabine has been demonstrated to have
activity in relapsed ovarian cancer in three recently published
phase II trials (Boehmer and Jaeger, 2002; Vasey et al, 2003;
Rischin et al, 2004). In addition, we replaced the cisplatin with
carboplatin to make the regimen more convenient for patients.
The aim of this study was to identify the maximum tolerated
dose (MTD) of capecitabine in combination with epirubicin and
carboplatin in patients with relapsed ovarian cancer. We planned
to identify safe doses of the drugs in this combination so that a
phase-III trial could be performed. We also evaluated the response
rate to carboplatin, capecitabine and epirubicin (ECarboX) as a
secondary end point.
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sPATIENTS AND METHODS
Patients were eligible if they had recurrent, histologically verified
epithelial ovarian carcinomas, had not received more than two
lines of chemotherapy and the treatment-free interval between the
cessation of the previous chemotherapy and documented relapse
exceeded 6 months.
Additional inclusion criteria were: age 18–80 years, ECOG
performance status 0–2, life expectancy 43 months, measurable
disease as assessed by CT in accordance with WHO guidelines,
GFRX60mlmin
 1 as measured by EDTA clearance or 24h urine
collection, bilirubin o2 times ULN, adequate bone marrow
function with WBC43000ml
 1, neutrophils 41500ml
 1, platelets
4100000ml
 1. Fully informed written consent was obtained from
all patients.
Patients were excluded for any serious uncontrolled medical
condition, a significantly abnormal ECG or cardiac history of
having a LVEFoLLN measured by MUGA scan or echocardio-
gram, or any medical or psychiatric condition, which would impair
the patients’ ability to give informed consent.
The protocol and the consent form were approved by the local
institutional ethics committee and protocol review board.
Treatment plan
Carboplatin was administered at a dose level of AUC5 intrave-
nously over a 1h infusion once every 3 weeks, epirubicin was given
as an intravenous bolus at a dose of 50mgm
 2 once every 3 weeks.
Administration of capecitabine was by the oral route and the doses
to be used in successive cohorts of patients were: capecitabine
375mgm
 2 BD (level 1), 500mgm
 2 BD (level 2) daily throughout
a 21-day cycle, and 625mgm
 2 BD (level 3) for days 1–14 of a 21-
day cycle. The decision to increase from level 1 to 2 was based on
the toxicity experienced in the first cycle of each cohort of three
patients. Escalation was to be carried out if dose-limiting toxicity
was not seen in the first three patients in each cohort. There were
two additional dose levels ( 1 and  2). Patients treated at these
dose levels received capecitabine for days 1–14 on a 21-day cycle
at 500mgm
 2 BD (level  1) and 375mgm
 2 BD (level  2) daily,
respectively. These dose levels were introduced when it became
clear that a 14 rather than 21-day schedule for capecitabine was
necessary if this three-drug regimen was to be administered safely.
All patients received prophylactic antiemetic therapy prior to
administration of carboplatin.
Six cycles of chemotherapy were planned for each responding
patient or those with stable disease. Criteria for withdrawal from
the study were as follows: intolerable side effects as judged by the
investigator or the patient, patient decision to discontinue
treatment for any reason, recurrent grade 3 or 4 drug-related
toxicity despite dose modifications, progression of tumour and
serious allergic reactions to any of the study drugs. Dose
reductions for haematological toxicity were performed according
to the protocol. Patients who withdrew from the study were
assessed for toxicity and response. Dose limiting toxicity (DLT)
was defined as grade IV myelotoxicity, which was either prolonged
(47 days) or complicated by bleeding or infection, or grade III
nonhaematological toxicity occurring in the first cycle.
Assessment of safety and efficacy
Toxicity and adverse events were reported according to NCIC-CTC
after each cycle.
Response was assessed by CT according to WHO criteria after
cycle 3 and 6; in addition, tumour marker CA-125 was used to
monitor response and was measured before each cycle. Complete
response was defined as normalisation of radiological appearances
and normalisation of CA-125.
RESULTS
In total, 18 patients with relapsed epithelial ovarian carcinoma and
a median age of 58 years (range, 43–70 years) were enrolled from
October 2002 until June 2004. A total of 13 patients had only
received one line of chemotherapy previously. The other five
patients received ECarboX as third-line treatment (Table 1). All
patients had a platinum-free interval 46 months and were thus
considered platinum-sensitive. The median platinum-free interval
was 18.6 months with a range of 8.7–55.4 months. One of the
patients had previously received radiotherapy to the brain for
cerebral metastases.
Three patients were assigned to dose level 1 (capecitabine
375mgm
 2 BD q21) and five patients to dose level 2 (capecitabine
500mgm
 2 BD q21). Following a protocol amendment, one
patient was treated at dose level 3 (capecitabine 625mgm
 2 BD
q14). Six patients received dose level  1 (capecitabine 500mgm
 2
BD q14) and three patients dose level  2 (capecitabine 375mgm
 2
BD q14), respectively.
Toxicity
At dose level 1, no DLT was experienced in the first cycle, although
one patient had grade 3 neutropenia and required subsequent dose
delays and dose reductions as per protocol. Another patient
experienced grade 3 diarrhoea and recurrent episodes of
neutropenia on cycles 2 and 4. She required a 450% dose
reduction of capecitabine and epirubicin and was treated off-study
after cycle 4 due to the delays of treatment. She did however have a
complete response.
At dose level 2, the cohort was expanded to five patients after
one patient had experienced a DLT (bleeding) during the first cycle
and required a 1-week delay of cycle 2. Two out of five patients
suffered from prolonged neutropenia following the first cycle,
which prevented retreatment with carboplatin on day 22. One of
these patients had another 3-week delay of her third cycle due to
grade 3 neutropenia and therefore came off-trial; she had
progressive disease after cycle three. Another patient experienced
grade 3 fatigue.
Following a protocol amendment due to the high rate of
prolonged grade 3 neutropenia, we treated patients with a
shortened schedule of capecitabine (14 out of 21 days). One
patient was treated at 625mgm
 2 BD for 14 days on a 21-day cycle
(level 3). She developed small bowel obstruction following the
administration of the first cycle of chemotherapy and required
surgery; she became neutropenic while awaiting surgery. The
patient was subsequently treated off-study with another four
courses at reduced dose and achieved a complete response. No
further patients were enrolled at this dose level as this severe
adverse event was felt to represent DLT.
Three out of six patients on dose level  1 required delays of day
22 due to prolonged grade 3 neutropenia, one had grade 3
thrombocytopenia and one grade 3 palmar-plantar-syndrome
(PPS). All other side effects were infrequent. After another dose
de-escalation, three patients were treated at level  2: one patient
had grade 4 stomatitis and one grade 3 neutropenia.
A total of 37 cycles of chemotherapy (out of 77 delivered on
study) had to be postponed due to toxicity. The median delay was
2 weeks per patient (range 0–5 weeks).
Table 1 Patient characteristics
Total patients 18
Second line treatment 13
Third line treatment 5
Median age 58 years (range, 43–70 years)
Platinum-free interval 18.6 months (range, 8.7–55.4 months)
Combination chemotherapy with ECarboX
C Rothermundt et al
75
British Journal of Cancer (2006) 94(1), 74–78 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sThe MTD was dose level 2 with capecitabine given at 500mgm
 2
BD for 21 days of a 21-day cycle. This schedule was not considered
suitable for taking forward to a larger multicentre trial because
of the frequent incidence of prolonged neutropenia. 14-day courses
of capecitabine were better tolerated; this schedule, however,
still caused Grade 3/4 haematological toxicity requiring dose
reductions and delays in 60% (six out of 10) of the patients
(Table 2).
Efficacy
In total, 11 patients (61.1%) showed either a complete (three
patients; 16.7%) or a partial response (eight patients; 44.4%), five
(27.7%) had stable disease. Only two (11.1%) of the patients had
progressive disease on treatment.
The median progression-free survival was 8.3 months, the
median follow-up time was 18 months (range 7.3–27.2 months).
Median overall survival has not yet been reached and 14 patients
are still alive.
DISCUSSION
We have performed a phase I/II trial using carboplatin, epirubicin
and capecitabine in platinum-sensitive patients with relapsed
epithelial ovarian cancer. The rationale behind this regimen
was that we had previously demonstrated a high response rate in
patients treated with ECF for relapsed ovarian cancer at the
Royal Marsden Hospital (Webb et al, 2000), and wanted to
investigate the feasibility of a more convenient route of
administration for a fluoropyrimidine. We used capecitabine
instead of 5-FU as this enables delivery of the fluoropyrimidine
in an oral form rather than via a continuous infusion requiring a
PICC line, without compromising on efficacy as shown for
colorectal cancer in randomised trials (Hoff et al, 2001; Van
Cutsem et al, 2001). We initially chose to administer continuous
capecitabine to mirror continuously infused 5-FU, but this proved
impractical.
In addition, carboplatin has been shown to be equally active as
cisplatin in advanced ovarian cancer (Swenerton et al, 1992; Taylor
et al, 1994; Ozols et al, 2003), but is less toxic and easier to
administer. This was the reason why we changed the cisplatin to
carboplatin for the ECarboX regimen.
We found the ECarboX regimen to be active with three patients
having a CR and eight patients a PR, giving an overall response
rate (ORR) of 61.1%. CR was seen in patients at dose level 1 and
dose level 3, PR was seen on all other dose levels. The median
progression-free survival of 8.3 months is consistent with the
results seen in this patient group in other phase I/II trials (Kose
et al, 2005).
However, ECarboX proved problematic to deliver as prescribed.
The overall toxicity was high in terms of haematological side
effects, although surprisingly no major infectious complications
arose from the neutropenic episodes. Prolonged myelotoxicity was
a significant feature even when administration of capecitabine was
shortened. All other side effects were infrequent and manageable.
One patient’s treatment was complicated by a cerebrovascular
event and a deep venous thrombosis during cycle two. She was
taken off study and treated with single-agent carboplatin. There
are reports suggesting capecitabine can induce acute coronary
syndromes (Schnetzler et al, 2001; Frickhofen et al, 2002), but no
reports of cerebrovascular events caused by capecitabine exist. It
remains unclear whether this patient’s CVA was related to
chemotherapy. The patient who developed intestinal obstruction
following the first course of treatment was thought to have disease
progression rather than a side effect from the regimen.
The management of patients with platinum-sensitive relapsed
ovarian cancer is receiving increasing attention. A retrospective
analysis (Dizon et al, 2002) of patients who received carboplatin/
paclitaxel at relapse demonstrated an OR of 69.7% and a
progression-free interval of 13 months. A total of 61.9% of these
patients had already received carboplatin/paclitaxel as first-line
treatment. However, 77% had a treatment-free interval 412
months and therefore would be considered good-risk patients.
Toxicity was acceptable although six patients required admission
to hospital for adverse events.
The ICON4/AGO-OVAR-2.2 trial investigated carboplatin/pacli-
taxel vs conventional platinum-based chemotherapy in women
with relapsed ovarian cancer (Parmar et al, 2003). In this trial,
about 40% of patients had received a platinum/paclitaxel
combination previously as first-line treatment. Response rates
were higher in the carboplatin/paclitaxel arm (OR 66 vs 54%,
P¼0.06) as was the median progression-free survival (12 vs 9
months) and overall survival (29 vs 24 months, HR¼0.82,
P¼0.02).
However, there may be problems in re-treating patients with
carboplatin/paclitaxel at relapse when they have received this
combination at first line particularly if their treatment-free interval
is 6–12 months. These patients frequently have a degree of
residual peripheral neuropathy and have only just regained a
normal length of hair; repeating and possibly exacerbating the
former toxicity in a short space of time is not acceptable to many
patients and their physicians, especially since these patients have a
rather poor prognosis. Carboplatin/gemcitabine is a treatment
option for patients with a potentially platinum-sensitive relapse. In
a randomised study conducted by the AGO in 356 patients, the
median progression-free survival was 8.6 months for patients
treated with carboplatin/gemcitabine and 5.8 months for those
receiving single-agent carboplatin, the response rate in the
combination arm was 47.2 and 30.9% for carboplatin alone
(Pfisterer et al, 2005).
In the context of these different regimens, other combinations
such as ECarboX are worthy of consideration. However, toxicity
Table 2 Toxicities (Grade 3/4)
Dose level 1 2 3  1  2 Summary
Capecitabine (mgm
 2 BD) 375 q21 500 q21 625 q14 500 q14 375 q14
Patient number n¼3 n¼5 n¼1 n¼6 n¼3 n¼18
Neutropenia grade 2 2131 9
Thrombocytopenia grade 11
Stomatitis grade 11
Diarrhoea 1 1
Fatigue 1 1
PPS 11
Median delay (weeks) (range) 3 (0–4) 2 (1–4) 2 1 (0–2) 3 (1–5) 2 (0–5)
Combination chemotherapy with ECarboX
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whether the potential risks outweigh the benefits.
One option would be to omit the anthracycline from the
ECarboX regimen. Such an approach is supported by data from the
Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) group
trial and the NSGO-EORTC-NCIC CTG gynaecological cancer
intergroup trial. These were two large randomised trials of first-
line chemotherapy, both of which have shown that the addition of
epirubicin to carboplatin/paclitaxel is of no benefit (Kristensen
et al, 2003; Du Bois et al, 2004).
The addition of epirubicin to a two-drug combination in the
second-line setting may therefore be of doubtful value. Conse-
quently we are currently evaluating the use of carboplatin in
combination with capecitabine in a phase-2 trial. This two-drug
combination may prove to be a suitable candidate for further
randomised trials in relapsed ovarian cancer.
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